PASSAGE BIO, INC. Income Tax Examination, Penalties and Interest Expense
PASSAGE BIO, INC. (PASG) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Expense Statement
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-09-03
- PASSAGE BIO, INC. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- PASSAGE BIO, INC. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
- PASSAGE BIO, INC. income tax examination, penalties and interest expense for fiscal 2021 was $0.00.
- PASSAGE BIO, INC. income tax examination, penalties and interest expense for fiscal 2020 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 S-4/A · filed 2026-09-03 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-04 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-04 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-03 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |